Cadila Healthcare receives US FDA's EIR report for facility in Ahmedabad SEZ

The pharmaceutical company Cadila Healthcare Ltd has received an establishment inspection report (EIR) from the US drug regulator for its oral solid dosage drug manufacturing plant located at SEZ, Ahmedabad. “The company's oral solid dosage drug manufacturing plant located at SEZ, Ahmedabad has received an EIR from the US Food and Drug Administration (FDA) following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised,” said Cadila Healthcare in a BSE filing.

The plant, for which EIR has been received by the company, is a separate manufacturing unit and is not a part of the Moraiya formulations manufacturing facility, it added.